TNONWHIGH SIGNALOPERATIONAL10-K

TNONW doubled its outstanding shares from 5.6M to 11.3M while completing a significant acquisition of SiVantage assets in August 2025, marking a major expansion phase despite burning through 42% of its cash reserves.

The 102% increase in outstanding shares suggests either a major equity raise or stock-based acquisition financing, which would significantly dilute existing shareholders. Combined with the SiVantage acquisition and substantial increases in receivables and inventory, this indicates aggressive growth execution but at the cost of substantial shareholder dilution and cash depletion.

Comparing 2026-03-27 vs 2025-03-26View on EDGAR →
FINANCIAL ANALYSIS

The company shows mixed operational performance with revenue growing 20% and gross profit expanding 38%, while simultaneously burning through $2.7M in cash (42% decline) and increasing total liabilities by 48% to $5.7M. The dramatic 97% increase in accounts receivable and 74% increase in inventory, coupled with rising current liabilities, suggests rapid business expansion following the acquisition but raises working capital management concerns. Despite revenue growth, the massive share dilution and deteriorating cash position signal potential financing pressures ahead.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+96.8%
$863K$1.7M

Receivables surged 96.8% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Interest Expense
P&L
-94.1%
$354K$21K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Inventory
Balance Sheet
+73.9%
$606K$1.1M

Inventory surged 73.9% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Liabilities
Balance Sheet
+71.9%
$1.9M$3.2M

Current liabilities surged 71.9% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+47.7%
$3.9M$5.7M

Liabilities grew 47.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Capital Expenditure
Cash Flow
+46.8%
$186K$273K

Capital expenditure jumped 46.8% — major investment cycle underway; assess returns on deployment.

Cash & Equivalents
Balance Sheet
-42.5%
$6.5M$3.8M

Cash declined 42.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Gross Profit
P&L
+37.8%
$1.7M$2.4M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+20.4%
$3.3M$3.9M

Revenue growing 20.4% — solid top-line momentum, watch margins for quality of growth.

Current Assets
Balance Sheet
-17.6%
$8.2M$6.8M

Current assets declined 17.6% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-26
ADDED
As of March 27, 2026, the registrant had a total of 11,296,378 shares of its common stock, $0.001 par value per share, outstanding.
( we or the Company ) was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California.
We are a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders.
We currently offer two systems to treat a diseased sacroiliac joint (the SI Joint ).
We have developed The Catamaran SI Joint Fusion System ( The Catamaran System ) that offers a novel, less invasive approach to the SI Joint using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain.
+7 more — sign up free →
REMOVED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
As of March 26, 2025, the registrant had a total of 5,584,965 shares of its common stock, $0.001 par value per share, outstanding.
(the Company ), was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California.
The Company is a medical device company that has developed The Catamaran SI Joint Fusion System ( The Catamaran System ) that offers a novel, less invasive approach to the sacroiliac joint (the SI Joint ) using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain.
For patients whose chronic lower back pain stems from the Sacroiliac Joint ( SI-Joint ), our experience in both clinical trials and commercial settings indicates the system to be introduced by Tenon could be beneficial for patients who are properly diagnosed and screened for surgery by trained healthcare providers.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →